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CYCLOSPORINE (CyA) is a novel cyclic polypeptide with potent immunosup-
pressive properties.1.2 Cy A is presently used 
with steroids to prevent the rejection of trans-
planted kidneys,3 livers,4 and heartsY This 
drug is primarily eliminated from the body by 
hepatic metabolism, and biliary excretion is 
the major route of CyA elimination in ani-
mals. 7 In humans, enterohepatic recycling of 
CyA has been suggested because of the pres-
ence of a second peak in CyT (CyA plus 
. metabolites measured by radioimmunoassay 
[RIA)) plasma concentrations and the 
appearance of the drug in the ileostomy drain-
age of one patient.8 We have observed 
increases in CyA blood levels (parent com-
pound measured by high-pressure liquid chro-
matography [HPLC]) following T-tube 
clamping in liver transplant patients, which is 
also indicative of possible enterohepatic recy-
cling of Cy A. In order for Cy A to undergo any 
significant enterohepatic recirculation, large 
amounts of CyA must be excreted in the bile. 
In the present study, we quantitated the bil-
iary excretion of CyA and CyT in adult liver 
transplant patients in order to determine 
whether CyA undergoes significant enterohe-
patic recycling. 
MATERIALS AND METHODS 
Eighteen biliary excretion studies were performed in 13 
patients (12 liver transplant recipients and one liver 
disease patient) with aT-tube in their common bile ducts. 
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CyA was administered either as an intravenous (IV) 
infusion (130 to 150 mg; n - 7), as a combination of IV 
infusion and oral dose (70 to 150 mg I V, 300 to 700 mg 
orally; n = 3). or as an oral dose (400 to 600 mg; n - 8). 
Prior to drug administration. the T-tube was drained and 
the total bile output over the study period of eight to 24 
hours was collected at one- to four-hour intervals. The 
total bile volume in each collection was measured. Ali-
quots of the bile samples were kept frozen at - 20 °C until 
being analyzed for CyA and CyT. HPLC was used to 
analyze CyA in samples from all of the patients. Samples 
from four patients were·also analyzed for CyT by RIA. 
Bile samples (0.1 to 1.0 mL) were extracted and 
assayed following minor modification of the HPLC proce-
dure of Sawchuk and Cartier.9 RIA was performed using 
a kit provided by Sandoz, Inc (East Hanover, NJ) accord-
ing to a procedure described by Donatsch et ai, 10 following 
I :20 and 1 :50 dilution of the bile samples. Standards were 
prepared for both methods in blank bile. 
Biliary excretion studies were peiformed in patients 
with varying degrees of liver function, as indicated by 
total serum bilirubin concentrations. Patients with a total 
bilirubin concentration of 1 mgj dL or less were consid-
ered to have normal liver function. Patients with a total 
serum bilirubin concentration of greater than 1 mgjdL 
were considered to have poor liver function. Three studies 
were performed in patients with normal liver function, 
and the remaining studies were carried out in patients 
whose liver function was poor. Bile output, bile CyA and 
CyT concentrations, and the total amounts of CyA and 
CyT excreted in bile was compared between patient 
groups with normal and poor liver function, using a 
Student's I test, assuming a level of significance of P c:s 
.05. 
RESULTS 
Analysis of blank bile by HPLC confirmed 
the absence of any interfering materials in the 
bile. The standard curve for HPLC analysis of 
CyA in bile was run from 25 to 4,000 ng/mL. 
The coefficient of variation (n = 9) at 887 
ng/mL was 6.5%. For the RIA analysis of 
CyT, the standard curve was linear from 78 to 
2,500 ng/mL. The coefficient of variation 
(n = 6) at 611 ng/mL was 17.8%. The bile 
samples were dilu ted to ensure that the results 
of the analysis were in the linear range of the 
standard curve for both HPLC and RIA. 
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Table 1. Biliary Excretion of Cyclosporine 
Total Amount of 
Dose (mgl Total Duration of Total Cyclosporine in Bile (mgl 
Study Bilirubin Bile Collection Bile Volume 
No. IV Oral (mg/dLi 
1 150 25.8 
2 150 
3 150 
4 130 24.6 
5 140 13.7 
6 150 4.3 
7 150 300 24.0 
8 100 700 14.8 
9 70 300 2.5 
10 600 2.5 
11 400 7.9 
12 550 5.8 
13 600 2.5 
14 500 0.5 
15 500 1.0 
16 400 1.0 
17* 730 18.4 
18* 144 18.4 
'Pretransplant, liver disease patient. 
The total volume of bile collected over one 
dosing interval ranged from 13.5 to 417.5 ml 
(Table 1). Patients with normal liver function 
had higher bile output than patients with poor 
liver function (24.1 mL/h v 7.6 mL/h; P < 
.05). 
The maximum bile concentration of CyA 
ranged from 32 ng/mL in a patient with 
severe liver disease to 5,212 ng/mL in a liver 
transplant recipient with normal hepatic func-
tion. The total amount of CyA excreted in the 
bile over a dosing interval ranged from 0.003 
to 0.814 mg.· There was a positive linear 
correlation between the bile output and the 
total amount of cyclosporine excreted in the 
bile (r = .686; P < .0 I). The amount of 
(hi (mLi HPLC (CyAI RIA (CyTI 
12 17.0 0.031 
12 13.5 0.025 
12 23.0 0.028 
8 53.5 0.208 
8 54.5 0.100 2.990 
13 59.0 0.097 
8 14.5 0.013 
12 50.5 0.035 0.980 
12 143.0 0.177 6.900 
12 280.0 0.222 
13 40.2 0.053 1.200 
13 239.0 0.092 
12 168.0 0.195 
12 417.5 1.052 
12 350.5 0.501 
12 97.7 0.814 
24 129.0 0.003 
23 83.0 0.005 
cyclosporine excreted in the bile in patients 
with normal liver function was greater than 
that excreted in patients whose liver function 
was poor at the time of the study (789 J.Lg v 98 
.ug; P < .01). The patient with severe liver 
disease who was studied pretransplant had the 
lowest maximum bile concentration of CyA 
and excreted the smallest amount of Cy A (3.7 
.ug) in the bile. A negative linear correlation 
was observed between serum bilirubin and the 
total amount of CyA excreted in the bile (r = 
-.597; P < .01). The total amount of CyA 
excreted in the bile over one dosing interval 
represents less than 1 '1(, of the administered 
dose in all of the patients studied (Table 2). 
The concentration of CyT in bile ranged 
Table 2. Effect of Liver FunctIon and Route of Administration on Cyclosporine Biliary Excretion 
No. Route of 
Bile Drainage 
of CyA mL/Dosing 
Status of Subjects Studies· Administration Interval 
Poor liver function 6 IV 37 
Poor liver function 3 IV and PO 69 
Poor liver function 4 PO 182 
Normal liver function 3 PO 289 
All values reported are the means for each group. PO, per orally. 
'Excluding the pretransplant studies. 
tBased on an assumed oral bioavailability of 20%. 
mL/h 
3.75 
6.0 
14.7 
24.1 
Dose 
Excreted Absorbed 
Amount of in Bile Dose Excreted 
eyA Excreted as eyA in Bile as CyA 
(mgl 1%1 (%1 
0.082 0.059 0.059 
0.075 0.018 0.053 t 
0.141 0.025 0, 124t 
0,789 0.170 O.85O t 
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from 9,280 to 61,300 ng/ mL, as measured by 
RIA. The maximum bile CyT concentration 
measured by RIA was 18 to 36 times higher 
than the CyA concentration by HPLC mea-
surements. The total amount of CyT excreted 
in the bile when measured by RIA ranged 
from 0.980 to 6.900 mg, with a mean of 3.018 
mg. The ratio of the total amount of CyT to 
CyA excreted in bile ranged from 23:1 to 39:1, 
with a mean of 30: 1. 
DISCUSSION 
Cyclosporine and steroids are the primary 
immunosuppressants used in heart, liver, and 
kidney transplant patients. Very little infor-
mation is available on CyA kinetics in trans-
plant recipients. Urinary excretion of CyA 
and CyT is a minor elimination pathway in 
dogs, rats, and humans. In dogs, most of the 
orally administered radioactive CyA is elimi-
nated in the feces. 7 More than 50% of the 
intravenously administered radioactive CyA 
is excreted in rat bile.7 In humans, indirect 
evidence for the involvement of bile in CyT 
elimination has been obtained from the analy-
sis of ileostomy drainage.8 This drainage 
accounted for 61.5% (measured as CyT) of 
the orally administered dose of CyA in one 
patient. As the drug was administered orally, 
unabsorbed drug may account partially for 
this observation. Moreover, RIA was used to 
analyze the ileostomy drainage. At present, no 
data on the amount of intact drug excreted in 
the bile are available. 
In our study, we obtained a direct estima te 
of the biliary excretion of CyA and CyT in 
adult liver transplant patients with aT-tube. 
The concentration of CyA and CyT in bile 
was greater than the concentrations in blood. 
However, less than 1 % of the administered 
dose of CyA was excreted in the bile during 
one dosing interval. The amount of CyA 
excreted in bile was highly variable and was 
partially dependent on the funtional status of 
the liver as well as the volume of bile. Patients 
with poor liver function had a low bile output 
and a low concentration of drug in their bile. 
Patients with normal liver function had the 
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highest bile output and higher drug concen-
trations in their bile. One patient with liver 
disease who was studied pretransplant 
excreted the least amount of CyA in his bile. 
This may be due to a combination of poor 
absorption (bioavailability was 3%) and poor 
excretory capacity of the diseased liver in this 
patient. 
There was no significant difference in the 
percentage of the dose excreted in the bile 
following oral and rv administration of CyA 
in patients with poor liver function. Increases 
in the blood CyA and CyT concentrations 
following T-tube clamping could be rational-
ized on the basis of a possible increase in the 
absorption of CyA due to increased amounts 
of bile being <;lvailable to facilitate the absorp-
tion of fat-soluble cyclosporine. 
Analysis of bile by RIA revealed the pres-
ence of large amounts of CyT. The CyT:CyA 
concentration ratio of 18-36:1 in the bile as 
compared to a ratio of 2-5: 1 in blood indicates 
that relatively greater amounts of CyA 
metabolites are excreted in the bile. The 
amount of CyT excreted in the bile as deter-
mined by RIA is 30 times greater than that 
measured by HPLC. RIA measurements of 
bile and blood are an underestimate of the 
total amount of CyA and its metabolites, as 
various CyA metabolites do not interact with 
the antibodies used in the RIA to the same 
extent that the intact parent CyA does. 
In our patients with normal liver function, 
bile collection represented more than half of 
the estimated normal bile output. Using a 
normal bile output of 500 mL in a l2-hour 
dosing interval and a mean CyA bile concen-
tration of 2.73 Jlg/mL (as observed in patients 
with normal liver function), one can estimate 
that approximately 1.37 mg of CyA is 
excreted in the bile. This represents 0.29% of 
the orally administered dose (mean oral dose 
in patients with normal liver function, 467 
mg). CyA is incompletely absorbed following 
oral administration. Assuming a bioavailabil-
ity of 20%, one can ca1cula te the percentage of 
the dose absorbed that is excreted in the bile 
as 1.46. Therefore, a patient receiving 500 mg 
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of oral CyA with a bioavailability of 20% 
would excrete approximately 1.46 mg of CyA 
in the bile. The amount of CyT excreted 
would be nearly 30 times greater and thus, a 
total of 43.8 mg of CyT will be excreted in the 
bile. 
The low amount of parent CyA excreted in 
bile indicates that intact CyA is not likely to 
undergo any significant enterohepatic recy-
cling. These results differ from an earlier 
report that suggested the possibility of signifi-
cant enterohepatic recycling of CyA in 
humans. This discrepancy may be explained 
partially because of the use of RIA assay to 
measure CyA in plasma and ileostomy drain-
age. CyA metabolites may, however, undergo 
enterohepatic recycling and hence produce 
secondary plasma CyT peaks. Secondary 
blood peaks have also been observed in a few 
of our patients when CyA was measured by 
HPLC. From our present results, it appears 
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that mechanisms other than enterohepatic 
recirculation may be responsible for such 
observa tions. 
In conclusion, very little intact CyA is 
excreted in the bile of liver transplant recip-
ients. In contrast, a large amount of CyT 
(CyA plus metabolites) is excreted in the bile. 
Intact CyA is not likely to undergo any signif-
icant enterohepatic recycling in patients fol-
lowing liver transplantation. 
SUMMARY 
The biliary excretion of Cy A was studied in 
13 patients with externalized bile flow. Analy-
sis of bile by HPLC revealed that less than 1 % 
of an administered dose of Cy A is excreted in 
the bile. RIA analysis of bile revealed that 
large amounts of CyT are excreted in the bile. 
Enterohepatic recycling of CyA is unlikely in 
liver transplant patients, but CyA metabolites 
may be subject to this process. 
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